Navigation Links
Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
Date:8/14/2008

ews release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... ... July 24, 2015 , ... RURO’s ... modern scientific or pharmaceutical laboratory. FreezerPro® is an intuitive, fast, reliable and ... a sample is located even before opening the freezer door! Popular features ...
(Date:7/23/2015)... ... ... One hundred years ago this year, 18 model airplane clubs competed in the ... the Henry S. Villard Trophy. The Academy of Model Aeronautics has plans to reenact ... a Free Flight fantasy club worthy of taking home the Villard Trophy. After extensive ...
(Date:7/23/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... Holding Company Limited (Biohaven), are pleased to announce ... (IND) Application with the U.S. Food and Drug ... Portage holds 54% equity interest in Biohaven, a ... modulating agent and Biohaven has entered into an ...
(Date:7/23/2015)... , ... July 23, 2015 , ... Global Stem ... research in Santiago, Chile. The symposium will feature some of the world’s most ... day of high-level scientific discussion for medical professionals in general practice. , The ...
Breaking Biology Technology:RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 2RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 3RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 4Academy of Model Aeronautics to Start Online Fantasy Flight Competition 2Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 2Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 3Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 4Global Stem Cells Group Announces Plans to Hold International Symposium on Stem Cells and Regenerative Medicine in Santiago, Chile Sept. 3-4, 2015 2Global Stem Cells Group Announces Plans to Hold International Symposium on Stem Cells and Regenerative Medicine in Santiago, Chile Sept. 3-4, 2015 3
... Calif., May 1 TorreyPines Therapeutics, Inc. (Nasdaq: ... ended March 31, 2009. For the three-month ... Cash and cash equivalents totaled $6.3 million at March ... Ford as its financial advisor to assist in the evaluation ...
... Fincor (Pink Sheets: FINC) through a share ... leading company in the field of water technologies, enlarges its ... Fincor also acquired the WETTECH and Advanced Cavitation Technologies. ... several natural drugs to fight Malaria and Dengue fever and ...
... Board of Directors Also Appoints a New President and ... Perrin, Ph.D., was appointed chief executive officer and Maureen ... Institute (ALS TDI) during the annual meeting of its ... passing of Sean Scott, the Institute,s previous president, due ...
Cached Biology Technology:TorreyPines Therapeutics Reports First Quarter 2009 Financial Results 2TorreyPines Therapeutics Reports First Quarter 2009 Financial Results 3TorreyPines Therapeutics Reports First Quarter 2009 Financial Results 4Fincor (FINC) Makes a Share Transfer and Enters the Market With ACTRx a New Malaria and Dengue Fever Treatment 2ALS Therapy Development Institute, the World's Largest Non-Profit Biotech, Appoints Steve Perrin, Ph.D., as Chief Executive Officer 2ALS Therapy Development Institute, the World's Largest Non-Profit Biotech, Appoints Steve Perrin, Ph.D., as Chief Executive Officer 3
(Date:6/24/2015)... , June 24, 2015 The biologics safety ... major drivers for the market include growth of the ... new drug launches. Over the years, the number of ... 2001 and 2010, the FDA approved 225 drug applications ... WIPO, Europe accounted for 3,822 ...
(Date:6/24/2015)... 2015 Research and ... the "Huawei Ascend Mate 7 Fingerprint Sensor ... offering. Huawei,s technological choice for the ... than Apple,s and Samsung,s one. The Ascend Mate ... Fingerprint Cards, a main actor in capacitive sensing ...
(Date:6/23/2015)... , June 22, 2015 ... announced the addition of the "Body-Worn Temperature ... Growth, Trends and Forecast 2014 - 2020" ... offers strategic analysis of the global body-worn temperature ... has been segmented on the basis of types, ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... issue of Genes & Development, Dr. Mary Ellen Perry ... promising target for cancer therapies. , The p53 tumor ... many anticancer strategies aim to activate p53 in order ... of p53 and therefore an attractive target to modulate ...
... physicists at the University of California, San Diego has shown ... as it passes through tiny pores. The advance brings ... in the April issue of the journal Nano Letters, describes ... of hours at a potentially low cost, by measuring the ...
... serious suicide attempts or death by suicide generally decreases ... according to a new study led by Group Health ... The American Journal of Psychiatry. The study also found ... newer antidepressant medications is less than the risk posed ...
Cached Biology News:Nanopore method could revolutionize genome sequencing 2Nanopore method could revolutionize genome sequencing 3Suicide risk does not increase when adults start using antidepressants, study finds 2
... The DNA quantitation kit is used to ... the presence of RNA or protein. With this ... which can be detected with a VersaFluor or ... range of 10 ng per ml to 5 ...
... stimulating factors for assays of mouse hematopoietic ... fetal liver. Suitable for the growth ... when added to methylcellulose at a final ... Will also support growth of mouse ...
ImmunoPure Plus Immobilized Protein G, , , , Support: Cross-linked 6%, beaded agarose , Capacity: > 20 mg human IgG/ml of gel ...
...
Biology Products: